RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📣 Reminder: Greenwich LifeSciences (Nasdaq: GLSI) Investor Webinar Tomorrow at 4:15PM EST! Don't miss Greenwich LifeSciences, Inc.'s important investor webinar highlighting the latest global progress in the FLAMINGO-01 Phase III trial. 💡 Why Investors Should Tune In: ✅ Promising Preliminary Data: Early immune response results trending positively across multiple patient groups. ✅ Expanded Global Reach: 117 active sites across the U.S. and Europe, with more to come. ✅ Strategic Insights: Updates on commercialization pathways, regulatory strategies, and patent life extension plans for GLSI-100. 🎯 With GLSI-100 targeting the prevention of breast cancer recurrence, this could be a pivotal moment for Greenwich's future growth. 🔗 Register or learn more ahead of the event: https://lnkd.in/efUguQhq Breast Cancer Now Biotechnology Biotechnology News #RedChip #RedChat #GreenwichLS #BreastCancer #BiotechNews #Oncology #FinancialNews #CapitalMarkets

🚨 In times of uncertainty, gold has always been the ultimate safe-haven asset — and Nova Minerals Limited (Nasdaq: NVA) is sitting on a massive 9.9 million ounce gold resource in one at its Estelle Project in Alaska’s legendary Tintina Gold Belt. Nova Minerals' district-scale opportunity, currently valued at a fraction of its peers, also includes a rich antimony resource that offers additional upside as mineral supply chains tighten globally. 🎥 See why Nova Minerals Limited could be the next big gold story: 🔗 https://lnkd.in/e9wVnh2b Mines and Money Agriculture by S&P Global Commodity Insights Framework for Gold Mining & Production Investments 2015 - 2050 #NovaMinerals #Gold #SafeHaven #MiningStocks #GoldRush #PreciousMetals #RedChipClient #Alaska #TintinaGoldBelt

🚀 Calidi Biotherapeutics (NYSE American: CLDI): Pioneering a New Era in Systemic Antitumor Virotherapy At the AACR Journals 2025 Annual Meeting, Calidi Biotherapeutics unveiled the IL15 superagonist as the first payload delivered by its RTNova platform, setting the stage for a new standard for metastatic cancer treatment. 💡 Why This Matters for Investors: ✅ Breakthrough Technology: RTNova enables systemic delivery of virotherapies, targeting hard-to-reach metastatic tumors with high precision. ✅ Promising Preclinical Data: Single systemic administration led to increased complete tumor responses without severe systemic toxicity. ✅ Broad Platform Potential: RTNova’s adaptable design can deliver various therapeutic payloads for multiple tumor types, creating expansive market opportunities. 📄 Read the full announcement and view the AACR presentation here: https://lnkd.in/eFVyP4t7 California Institute for Regenerative Medicine (CIRM) Northwestern University City of Hope The Lancet Group Biotechnology Biotechnology News #BiotechStocks #CancerResearch #OncologyInnovation #ImmunoOncology #Investors

🥋 MMA.INC (NYSE American: MMA): Strategic Partnership with Clark Gracie Unlocks New Revenue Opportunities MMA.INC has partnered with Brazilian Jiu-Jitsu legend Clark Gracie—bringing global brand power to BJJLink and accelerating growth across 5,700+ new students and Gracie Allegiance affiliates worldwide. 🌎 💡 Why This Matters for Investors: ✅ Expanding Revenue Streams: Exclusive rollout of BJJLink to Gracie-affiliated gyms, unlocking subscription, transaction, and sponsorship opportunities. ✅ Global Scale: Tapping into the 640M global MMA fanbase with mobile-first technology connecting fans, fighters, coaches, and gyms. ✅ Product Evolution: Clark Gracie to co-develop the upcoming Community & Commerce Platform, launching in Q2 2025 to drive engagement and monetization. 📄 https://lnkd.in/e8UvP4y7 Athletic Ventures Sports Business Journal Events #BJJ #FinancialNews #CombatSports #Investing #SportsTech #GrowthStocks #ClarkGracie

🎶 Big Milestone for Venu Holding Corporation (NYSE American: VENU): Sunset Amphitheater Moves Forward with City Approval and Luxe FireSuites Launch! 🏟️ El Paso City Council has approved key amendments to VENU's public-private partnership, advancing the 12,500-seat Sunset Amphitheater project—poised to become a premier entertainment destination in the Cohen Entertainment District. 💡 Why This Matters to Investors: - $100M+ Private Investment: Increased commitment highlights strong financial backing. - Expanded Development: Site expands to 20 acres, enabling year-round events and enhanced amenities. - Economic Engine: Projected $2B+ economic impact in the first 10 years, fueling jobs, tourism, and regional growth. - Luxe FireSuites: Fractional ownership now available—offering exclusive access, luxury amenities, and potential financial returns. 🚀 With the venue anticipated to open in 2026, VENU is tapping into massive demand for upscale live entertainment experiences. 🔗 https://lnkd.in/etyVnNcn VenuesNow REAL ESTATE ARENA Troy Aikman EIGHT Elite Light Lager Mayor & Council, City of El Paso #SmallCapStocks #VENU #EntertainmentInvesting #Hospitality #ElPaso #SunsetAmphitheater #InvestorNews #LuxuryInvesting

🚨 Major Milestone: Better Choice Company (NYSE:BTTR) Completes SRx Merger, Rebrands as SRx Health Solutions (NYSE American: SRXH) 📢 Better Choice has closed its merger with SRx Health Solutions and completed an $8.8M private placement priced above market. The deal includes the issuance of 28.6M shares, propelling the company into a new era as a diversified global health and wellness provider. 🔄 What’s Changing: 📈 $8.8M in new funding from institutional investors at $2.18/share 🧬 Merger with SRx Health finalized 🔁 Name & ticker change: Better Choice becomes SRx Health Solutions (NYSE American: SRXH), effective April 30, 2025 💡 Why This Matters for Investors: This marks a strategic pivot into broader health and wellness markets, expanding beyond pet care into high-growth verticals for people and families, backed by institutional capital and a fresh corporate identity. 📄 Full Press Release: https://lnkd.in/e5upHtgQ PET HEALTH CARE Veterinary Practice #BTTR #CapitalMarket #PetWellness #InvestorUpdate #FinancialNews #EquityValue 

🚨 America’s next mineral crisis is here — and hardly anyone’s talking about it. China & Russia control global antimony supply — a critical mineral used in EVs & defense. But one company with a district-scale project in Alaska may hold the answer… and a multi-million-ounce gold deposit to boot. 🎥 Watch the latest Undiscovered Gems episode to learn more: 🔗 https://lnkd.in/e9wVnh2b Mines and Money Mining News S&P Global Commodity Insights #NovaMinerals #RedChipClient #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks

🚀 XTI Aerospace (Nasdaq: XTIA) National Security Veteran Joins to Advance TriFan 600 Strategy XTI Aerospace has added Preston Dunlap—former Chief Architect of the U.S. Space Force and Air Force—to its Corporate Advisory Board. With oversight of $70B in aerospace programs and a track record launching $250B in next-gen defense tech, Dunlap brings unparalleled insight to support TriFan 600's path to certification and commercialization. 💡 Why This Matters for Investors: - Defense-Ready Expertise: Dunlap’s leadership aligns TriFan 600 with potential military, medevac, and homeland security use cases. - Accelerating Certification: Strategic guidance aims to fast-track market entry for this hybrid VTOL aircraft. - Dual-Use Appeal: The TriFan’s runway-free, fixed-wing efficiency positions it for both commercial and defense demand. 📄 Learn More About the Appointment: https://lnkd.in/e4TWFgWf Aerospace & Defense Technology News #AerospaceInnovation #DefenseStocks #eVTOL #NationalSecurity #AviationFuture

🚨 Connect Biopharma (Nasdaq: CNTB) to Showcase Respiratory Innovation at ATS 2025 Connect Biopharma will present four clinical posters at the American Thoracic Society 2025 International Conference, spotlighting promising data for its lead candidate rademikibart, a next-gen IL-4Rα antibody for asthma and COPD. 🧬 Why This Matters to Investors: - Strong Clinical Data: Phase 2b data shows rapid, clinically meaningful lung function improvement—FEV₁ gains seen within 24 hours. - Addressing Large, Unmet Need: Targeting acute exacerbations in ~2.3M U.S. asthma and COPD patients annually—an underserved, high-need market. - Upcoming Milestone: Connect Biopharma's parallel Phase 2 trials set to begin in Q2 2025, accelerating rademikibart’s path through the clinic. 📄 Full press release and presentation details: 🔗 https://lnkd.in/e_CS96Wk Asthma.net Biotechnology Biotechnology News #CNTB #Asthma #COPD #Biotech #ClinicalTrials #RespiratoryCare #Investing #finance